Bristol-Myers Squibb (BMS) is a large-cap biopharmaceutical company that discovers, develops, and sells branded medicines for serious diseases across six therapeutic areas: oncology, hematology, immunology, cardiovascular, neuroscience, and select other areas. BMS sells primarily to wholesalers, specialty pharmacies, and distributors, who in turn supply hospitals, clinics, and pharmacies. BMS organizes its products into a Growth Portfolio of newer, patent-protected drugs and a Legacy Portfolio of older drugs facing generic and biosimilar competition. Key growth products include Opdivo, a PD-1 checkpoint inhibitor approved across 30+ oncology indications and BMS's largest product; Eliquis, a leading oral anticoagulant co-developed with Pfizer; Reblozyl, a biologic for anemia in blood disorders co-commercialized with Merck; Breyanzi, a CAR-T cell therapy approved across five B-cell blood cancers; Camzyos, an oral treatment for a rare heart condition; and Cobenfy, the first novel mechanism approved for schizophrenia in over 30 years. The legacy portfolio — led by Revlimid, Pomalyst, Sprycel, and Abraxane — is in rapid decline as patents expire. BMS's core strategic challenge is growing its newer products fast enough to offset this multi-billion-dollar legacy revenue decline. BMS supplements internal R&D with acquisitions, partnerships, and licensing deals, and spends roughly $10B annually on R&D. Business development is management's top capital allocation priority.